Ralliant (NYSE:RAL) Announces Quarterly Earnings Results

Ralliant (NYSE:RAL) issued its quarterly earnings results on Wednesday. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02, Zacks reports. The company had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Ralliant updated its Q1 2026 guidance to 0.460-0.520 EPS and its FY 2026 guidance to 2.220-2.420 EPS.

Ralliant Stock Performance

NYSE RAL traded up $0.14 during trading on Friday, reaching $38.53. 962,942 shares of the company’s stock were exchanged, compared to its average volume of 1,703,446. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The business has a 50 day moving average price of $51.72 and a 200-day moving average price of $46.77. The stock has a market capitalization of $4.35 billion and a P/E ratio of 30.33.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Analyst Ratings Changes

RAL has been the topic of several recent research reports. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $53.00 to $61.00 in a research note on Monday, December 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Truist Financial set a $49.00 price objective on Ralliant in a research note on Friday. Oppenheimer set a $50.00 price target on Ralliant in a report on Friday. Finally, Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Friday. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Viking Global Investors LP bought a new position in Ralliant during the 2nd quarter worth $257,200,000. State Street Corp acquired a new position in shares of Ralliant in the 2nd quarter worth approximately $213,096,000. Invesco Ltd. boosted its stake in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock valued at $169,309,000 after purchasing an additional 1,835,128 shares during the last quarter. UBS Group AG raised its stake in Ralliant by 660.3% during the third quarter. UBS Group AG now owns 1,865,072 shares of the company’s stock worth $81,560,000 after buying an additional 1,619,770 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Ralliant by 661.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,720,763 shares of the company’s stock valued at $75,249,000 after buying an additional 1,494,666 shares during the period.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, signaling some analyst conviction that shares have upside from current levels. The Fly: Vertical Research Upgrade
• Positive Sentiment: Ralliant earned a relative strength rating upgrade and hit a key technical benchmark, which can attract momentum buyers or ETFs that screen on technical signals. MSN: Relative Strength Upgrade
• Neutral Sentiment: Q4 results slightly beat consensus on EPS ($0.69 vs $0.67) and revenue ($554.6M vs $543M), showing modest operating resilience before one‑time items. Investors will focus on underlying segment trends disclosed in the call/slide deck. Ralliant Q4 Press Release / Slides
• Neutral Sentiment: The company issued FY‑2026 EPS guidance (2.22–2.42) below Street expectations (2.71) while Q1 guidance was modestly shy of consensus; revenue targets were roughly in line. Guidance weakness is the principal driver for forward‑looking re‑rating. MarketBeat: Guidance Details
• Negative Sentiment: Ralliant took a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment tied to revised expectations for the EA Elektro‑Automatik acquisition; that charge produced a $1.4B net loss and prompted the stock to plunge on the print. This large write‑down raises questions about past acquisition assumptions and future earnings power. MarketWatch: $1.4B Impairment
• Negative Sentiment: Multiple law firms (Johnson Fistel, Holzer & Holzer, Block & Leviton) have announced investigations into whether Ralliant and its officers complied with securities laws after the impairment disclosure; such inquiries can prolong volatility and create legal/settlement risk. Newsfile: Johnson Fistel Investigation
• Negative Sentiment: Following the impairment/guidance headlines, shares fell to an all‑time low as some investors exited after the company swung to heavy losses, increasing downside momentum risk near current levels. InsiderMonkey: All‑Time Low

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.